G
Guoli Chen
Researcher at Pennsylvania State University
Publications - 3
Citations - 213
Guoli Chen is an academic researcher from Pennsylvania State University. The author has contributed to research in topics: Bladder cancer & Antigen. The author has an hindex of 3, co-authored 3 publications receiving 146 citations. Previous affiliations of Guoli Chen include Geisinger Medical Center.
Papers
More filters
Journal ArticleDOI
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
Joshua I. Warrick,Gottfrid Sjödahl,Matthew Kaag,Jay D. Raman,Suzanne B. Merrill,Lauren Shuman,Guoli Chen,Vonn Walter,David J. DeGraff +8 more
TL;DR: It is found that different areas from the same tumor are often molecularly different, particularly in the basal-squamous subtype, and this biological diversity must be taken into account when interpreting clinical molecular tests performed on bladder cancer samples.
Journal ArticleDOI
Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.
Huili Li,Qingzhao Zhang,Lauren Shuman,Matthew Kaag,Jay D. Raman,Suzanne B. Merrill,David J. DeGraff,Joshua I. Warrick,Guoli Chen,Guoli Chen +9 more
TL;DR: The immune high group is enriched in higher CD3, PD-L1, and genomically-unstable molecular subtype, suggesting it may respond to checkpoint inhibitors, and a degree of intratumoral heterogeneity in immune markers in bladder cancer is identified.
Journal ArticleDOI
Repression of transcription factor AP-2 alpha by PPARγ reveals a novel transcriptional circuit in basal-squamous bladder cancer.
Hironobu Yamashita,Yuka Imamura Kawasawa,Lauren Shuman,Zongyu Zheng,Truc Tran,Vonn Walter,Joshua I. Warrick,Guoli Chen,Hikmat Al-Ahmadie,Matthew Kaag,Pak Kin Wong,Jay D. Raman,David J. DeGraff +12 more
TL;DR: These findings suggest PPARɣ inactivation, as well as TFAP2A andTFAP2C overexpression cooperate with other TFs to promote the basal-squamous transition during tumor progression, which is associated with increased lymph node metastasis and distant recurrence.